A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Mark S. Gelder, M.D. as senior vice president and chief medical officer. The addition of Dr. Gelder to A.P. Pharma’s executive team represents the Company’s continued efforts related to pre-commercialization activities for APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if approved.
“Mark will play a crucial role as A.P. Pharma’s chief medical officer as the organization continues to prepare for the potential commercialization of APF530,” said John B. Whelan, A.P. Pharma’s president and chief executive officer. “Mark’s medical and pharmaceutical acumen is well suited for the work that A.P. Pharma is doing in cancer supportive care. We welcome him to our executive team and look forward to adding his expertise to our pre-commercialization activities.”
Dr. Gelder, most recently, was the vice president and global head of medical affairs and pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare, Dr. Gelder was the vice president, global medical affairs oncology for Bayer Healthcare Pharmaceuticals, and was responsible for the global medical strategy supporting the launch of Nexavar®, Stivarga ®, and Alpharadin ® global launch programs. Dr. Gelder was also the global therapeutic area director of oncology at Wyeth, with a focus on the commercial launch of Torisel ®. Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, working on Sutent ®, and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received a bachelor’s of science degree from Colgate University, and his doctor of medicine from the University of Virginia’s School of Medicine.
“The impact of chemotherapy-induced nausea and vomiting on patient care is tremendous,” said Dr. Gelder. “Working in oncology, both on the patient care side as well as working in therapeutic research, has been a focus for me throughout my career. I believe that APF530 holds the promise to help address some of the most severe side effects from chemotherapy treatment, which can help patients adhere to their care regimen.”